Tag Archive for: prostate cancer

When the leak won’t quit: urinary incontinence in men

A Movember reminder that help is available

Movember is a good time to talk about men’s health issues that are often kept quiet. Urinary leakage is one of them. It can affect confidence, exercise, work, travel, intimacy and sleep. After prostate surgery, some leakage is common during recovery, but men do not have to simply put up with persistent or troublesome symptoms.

This article focuses on urinary incontinence after prostatectomy. It is general information, not a diagnosis or a substitute for advice from your own doctor.

What does “incontinence” mean?

Urinary incontinence means urine escapes when you do not intend it to. After prostate surgery, the most common pattern is stress urinary incontinence: leakage with coughing, sneezing, lifting, walking, standing up or exercise. The operation can affect the urinary sphincter and the support around the urethra.

Some men instead, or as well, experience urgency incontinence: a sudden, hard-to-delay urge followed by leakage. This may relate to an overactive bladder. Other causes: including infection, difficulty emptying the bladder, a narrowing at the bladder outlet or a medication effect. may also need consideration. The treatment depends on the pattern, so it is worth describing exactly when leakage happens.

What to expect after prostatectomy

Leakage is common soon after the catheter is removed and usually improves over time. Many men continue to regain control over the first 6–12 months, although recovery varies and some men have persistent leakage. A small amount of leakage can still be very disruptive, and heavier leakage deserves timely review rather than a wait-and-see approach without support.

If leakage is not improving, is affecting daily life, or you are worried, speak with your GP, urologist, continence nurse or pelvic health physiotherapist. You can ask for help at any stage of recovery.

Start with an assessment

A clinician will ask about the amount and timing of leakage, urgency, night-time symptoms, bowel habits, previous radiation or other procedures, and how much the problem affects you. A bladder diary and pad count or pad-weight test can help describe the pattern and severity. Examination, urine testing, bladder emptying checks, cystoscopy or urodynamic testing may be useful in selected cases—particularly before surgery or if the symptoms are not straightforward.

Assessment helps distinguish stress leakage from urgency or mixed symptoms, and checks for problems that should be treated before continence surgery.

Pelvic floor physiotherapy: learning the right muscles

Pelvic floor muscle training is commonly offered after radical prostatectomy and may also be started before surgery with your treating team’s advice. A pelvic health physiotherapist or continence nurse can show you how to find and correctly contract the muscles, then build a programme around your recovery. The aim is a controlled lift and squeeze around the back passage and base of the penis, followed by a full relaxation. Try not to hold your breath or tighten your buttocks, thighs or stomach.

A correct contraction should not hurt. Avoid repeatedly stopping your urine stream as an exercise; that can interfere with normal bladder emptying. Follow your surgeon’s instructions about when to begin or resume exercises, particularly while a catheter is in place. Some men benefit from learning a quick pelvic floor contraction before coughing, lifting or standing.

Training can help speed recovery and improve control, but it is not a guaranteed cure, and it may not overcome significant sphincter damage on its own. Keeping active safely, avoiding constipation and getting advice about continence products can make recovery more manageable. Do not deliberately dehydrate yourself; adequate fluid intake helps avoid concentrated urine and constipation. If caffeine or alcohol aggravates urgency, reducing it may help those symptoms.

Other non-surgical support

Absorbent pads or a male urinary sheath can help you stay active while recovery continues. A continence nurse can help with fit, skin care and practical use. A penile clamp may suit selected men for short periods, but it can restrict blood flow or injure skin and should only be used after professional advice. Medicines may help urgency or overactive bladder symptoms, but they do not repair a weakened urinary sphincter.

When is surgery considered?

If bothersome stress leakage is not improving despite conservative care, surgery can be discussed from around six months in selected men; persistent leakage is generally reviewed for surgical treatment by about 12 months. The timing should be individualised with your urologist, taking account of the severity and trajectory of leakage, cancer treatment plan, bladder and urethral health, and your preferences.

Two established operations are a male sling and an artificial urinary sphincter (AUS). Neither is right for every man, and both require a careful assessment and discussion of expected benefits, possible complications and the chance of future treatment.

Male sling

A sling is placed beneath the urethra to support it and improve its closure. It is generally considered for men with mild-to-moderate stress leakage, particularly when they have not had pelvic radiotherapy and do not have severe leakage. It does not have a pump to operate. A sling may not work as well for heavier leakage, and previous radiation or some other urethral procedures can reduce the chance of success. Some men continue to leak or may later need another procedure.

Artificial urinary sphincter

An AUS uses a fluid-filled cuff around the urethra, connected to a small pump placed in the scrotum. The cuff stays closed to prevent leakage. To urinate, the man presses the pump; the cuff opens temporarily and then closes again automatically. The device is a well-established option for moderate-to-severe stress leakage, and may also be considered for other degrees of troublesome leakage after discussion.

An AUS requires an operation and the ability to understand and operate the pump. It can substantially improve control, but it may not make every man completely dry. Infection, erosion or mechanical problems can occur, and the device can lose effectiveness over time. Further procedures to revise or replace it are common over a person’s lifetime. If you have an AUS, tell any doctor, nurse or hospital team before a urinary catheter or instrument is inserted, as special care is needed to avoid damaging the cuff or urethra.

Choosing between them

The choice depends on leakage severity, previous radiotherapy or urethral surgery, bladder function, hand function and cognition, anatomy, personal priorities and the surgeon’s assessment. In general, slings are most often discussed for mild-to-moderate leakage, while an AUS is often favoured for more significant leakage or after radiotherapy. Cystoscopy is usually part of the assessment before an operation; urodynamics may be useful where it could clarify the diagnosis or guide counselling.

The emotional side matters too

Wearing pads, planning every trip around a toilet, or worrying about leakage during exercise or sex can be isolating. These concerns are legitimate health issues, not a personal failure. A partner, GP, urologist, continence nurse or physiotherapist can help you find a practical next step. Movember is a reminder to check in with your mates—and to speak up about your own health as well.

When to seek prompt medical advice

Seek urgent medical advice if you cannot pass urine, develop fever or feel acutely unwell with urinary symptoms, notice visible blood in your urine, or develop new severe pain. If you have an AUS and develop pain, swelling, redness, difficulty urinating or a sudden change in leakage, contact your treating team promptly.

Key message

Urinary leakage after prostatectomy is common, but persistent leakage has treatment options. Pelvic floor physiotherapy is an important part of recovery; pads and other supports can help in the meantime; and selected men may benefit from a sling or artificial urinary sphincter. The first step is an open conversation and an assessment tailored to the type and severity of leakage.

Further information and references

  1. American Urological Association, GURS and SUFU. Incontinence after Prostate Treatment: Guideline (2019; amended 2024). AUA guideline PDF.
  2. European Association of Urology. Guidelines on the Management of Non-neurogenic Male LUTS, 2026: Disease Management. EAU guideline.
  3. Continence Health Australia. Bladder control after prostate surgery. Patient information.
  4. Prostate Cancer Foundation of Australia. Pre- and rehabilitation: urinary incontinence and pelvic floor exercises. PCFA resource.
  5. Cancer Council Australia. Managing side effects of prostate cancer treatment. Cancer Connect.

This information is educational and does not replace an individual consultation. Treatment decisions should be made with your treating health professional.

Movember and the digital rectal examination: does it still matter?

The digital rectal examination (DRE) has been part of prostate assessment for generations. It is also one of the tests men are most likely to dread, joke about, or avoid. As Movember prompts conversations about prostate health, it is worth asking what a DRE can actually tell us today and when it is useful.

The short answer: a DRE still has a place in clinical assessment, but it is not recommended as a routine add-on to PSA testing for every asymptomatic man. PSA blood testing is the main early-detection test. A DRE can add physical information in selected situations, and it remains one part of monitoring some men with known prostate cancer.

What is a DRE?

A DRE is a brief examination in which a clinician gently inserts a gloved, lubricated finger into the rectum to feel the back surface of the prostate. The clinician assesses features such as the prostate’s size, shape, firmness, symmetry and any distinct lump or irregular area. It may also give information about tenderness or other rectal findings.

The prostate sits in front of the rectum, so the examination can only feel part of the gland. It cannot reliably assess the whole prostate, and some cancers, particularly those in areas that cannot be reached by touch, may not be felt. A normal DRE therefore does not rule out prostate cancer.

What extra information can it provide?

PSA is a blood marker produced by prostate tissue. It helps estimate risk, but PSA alone does not show where a possible cancer is or how the prostate feels. A DRE gives the clinician a physical finding to interpret alongside the PSA result, symptoms, family history and, when indicated, MRI and biopsy.

A firm nodule, marked asymmetry, or an unusually hard or fixed-feeling area can increase concern and prompt further assessment, even if the PSA is not markedly raised. An abnormal DRE may also help estimate the clinical extent of a cancer and its likelihood of being more significant. But it is not a cancer diagnosis: benign enlargement, inflammation and examiner variation can affect what is felt. A suspicious finding usually needs further assessment, often including MRI and possibly biopsy.

DRE is not a substitute for PSA, MRI or biopsy. Nor does a normal examination provide a guarantee that cancer is absent.

Can it find cancers that produce little PSA?

Occasionally, prostate cancer is found after a suspicious DRE even when PSA is low. Some uncommon or poorly differentiated cancers can produce less PSA than expected. In the 2026 European Association of Urology guideline, a suspicious DRE with PSA at or below 4 ng/mL was associated with a positive predictive value ranging widely from 5% to 30% in the cited evidence. This shows why a distinctly abnormal examination should not automatically be dismissed because of a reassuring PSA.

That does not mean DRE is a dependable way to screen for low-PSA cancers. Many cancers cannot be felt, and DRE’s performance as a stand-alone screening test is limited. If symptoms, imaging or other clinical features raise concern, the clinician should consider the full picture rather than rely on either a normal PSA or a normal DRE alone.

Should every man having a PSA test also have a DRE?

No. The NHMRC-approved 2026 Guidelines for the Early Detection of Prostate Cancer in Australia suggest that DRE not be offered in primary care as a routine addition to PSA testing and risk assessment for asymptomatic men. The RACGP Red Book also advises against routine DRE as an addition to PSA testing in asymptomatic men seeking early detection.

This reflects evidence that routine DRE adds little to population early-detection pathways compared with PSA-based assessment, while it can create discomfort and deter some men from discussing testing. PSA testing itself is a choice to make after discussing potential benefits and harms with a GP; it is not an automatic test for everyone.

A DRE may still be appropriate when a person has symptoms, a concerning PSA result, an abnormality on imaging, or another clinical reason for a physical examination. A clinician should explain why it may help in that specific situation and discuss alternatives where appropriate.

What about men already on active surveillance?

Active surveillance is a monitoring approach for selected men with lower-risk prostate cancer, intended to identify evidence of meaningful change while avoiding or delaying treatment side effects when it is safe to do so.

The 2026 Australian guideline proposes periodic DRE alongside PSA measurements, MRI where appropriate and repeat biopsy when clinically indicated. A change in the examination may be one reason to bring forward MRI or biopsy. It is not, by itself, usually enough to decide that treatment should start. The European Association of Urology also includes DRE in surveillance protocols, while recognising that its frequency may be reduced in selected men with stable MRI and other reassuring findings. Monitoring plans vary with the cancer’s features, prior tests and the person’s circumstances.

Why is the DRE so famous, and why are some men apprehensive?

For many years, before PSA testing and prostate MRI were available, clinicians had fewer ways to assess the prostate. The DRE was a quick bedside examination that could identify a large or locally advanced abnormality. It became closely associated with “getting your prostate checked,” and popular culture has kept it in the spotlight.

When I discuss it with patients, I sometimes call DRE the “dreaded rectal examination” a little wordplay that can break the ice. It acknowledges the test’s reputation, but it is not a request to grin and bear it: I explain what I’m doing, ask permission, and stop if you ask.

The examination can feel intimate or embarrassing. Some men worry it will hurt, feel exposed, or be judged. Others have heard jokes that link the test to masculinity or sexuality. These concerns are understandable, but a DRE is a clinical examination; it says nothing about a person’s identity or sexuality. Many people find it awkward or uncomfortable rather than painful, although experiences differ.

You can ask the clinician to explain each step before starting, request a chaperone, discuss positioning, and ask them to stop at any time. Consent matters. You do not need to agree to an examination simply because you have come to talk about PSA testing.

What should I do this Movember?

If you are thinking about prostate testing, speak with your GP about your age, family history, health and preferences. Ask whether PSA testing is suitable for you and whether an examination would add useful information in your circumstances. If you have urinary symptoms, blood in your urine or semen, persistent unexplained pain, or another concern, arrange an assessment rather than waiting for a routine screening test.

Movember is a chance to make the conversation easier. The aim is not to insist that every man must have a DRE. It is to help each person understand the available tests, feel able to ask questions, and make an informed decision with their clinician.

This article provides general information and is not a substitute for personal medical advice.

References and further information

  1. Prostate Cancer Foundation of Australia. 2026 Guidelines for the Early Detection of Prostate Cancer in Australia. NHMRC-approved recommendations, 18 May 2026. See Recommendations 4.1 and 8.2.1.
  2. The Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice, 10th edition — prostate cancer. Recommendations updated 28 June 2024.
  3. European Association of Urology. EAU Guidelines on Prostate Cancer: Diagnostic Evaluation, 2026 edition.
  4. European Association of Urology. EAU Guidelines on Prostate Cancer: Treatment and active-surveillance follow-up, 2026 edition.
  5. Sajjad W, et al. Comparing the Performance of Digital Rectal Examination and Prostate-specific Antigen as a Screening Test for Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Oncology. 2024. PubMed.

Movember: PSA testing: what it can tell you, and what it can’t

An informed conversation with your GP can help you decide whether a PSA test is right for you. Your age, family history, general health and preferences all matter.

Movember is a good time to talk about men’s health, including prostate cancer. One of the most useful steps is often a simple conversation with your GP about prostate-specific antigen (PSA) testing. A PSA blood test can help identify men who may need further assessment, but it is not a yes-or-no cancer test. Understanding what it can and cannot show helps you make an informed choice.

What is PSA?

PSA is a protein made by cells in the prostate. A small amount normally enters the bloodstream, where it can be measured with a blood test. PSA is prostate-specific, but not cancer-specific: a higher result can occur with prostate cancer, but also with benign prostate enlargement, inflammation or infection, urinary retention, or after some urinary procedures. PSA levels also tend to rise with age.

A PSA test is different from a digital rectal examination (DRE). The blood test measures PSA. A DRE is an examination in which a clinician feels the prostate through the rectum. A DRE is not routinely required as an addition to PSA testing for an asymptomatic man under RACGP guidance, although examination may be useful when symptoms or other findings make it appropriate.

Why do we use PSA?

Prostate cancer may cause no symptoms in its early stages. PSA testing can identify a result that deserves a closer look before symptoms develop. Used thoughtfully, early detection may help find clinically significant cancer while treatment or monitoring options remain available.

There are limits and possible harms. PSA can be raised when cancer is not present, leading to anxiety, repeat tests, scans and sometimes biopsy. It can also find a slow-growing cancer that would never have caused a problem during a person’s lifetime. Diagnosis and treatment can have side effects, including changes to urinary continence and sexual function. The chance of benefit depends on a person’s risk, health and life expectancy. That is why Australian guidance recommends an informed discussion before testing rather than testing everyone automatically.

Is PSA a good marker for prostate disease or prostate cancer?

PSA is a useful risk marker, not a diagnosis. It can help estimate the chance of prostate cancer and guide whether further assessment is sensible. It is not a reliable general test for every prostate problem, and it cannot by itself distinguish cancer from benign enlargement or inflammation.

A low PSA lowers the chance of prostate cancer but does not make it zero. A raised PSA does not mean that cancer is present. If the result is higher than expected for a person’s age and risk, the GP will usually consider the whole picture and repeat the test before acting on a single result. Infection, inflammation, retention and recent instrumentation can affect the result, so timing and clinical context matter.

If PSA remains elevated, further assessment may include a clinical review, examination when appropriate, and prostate MRI. Current Australian guidance recommends multiparametric MRI before biopsy. A biopsy, when indicated, is what confirms whether cancer is present and provides information about its grade. Not everyone with a raised PSA needs a biopsy.

How often should PSA be tested?

Australia’s guidance has evolved. The RACGP’s Guidelines for preventive activities in general practice (Red Book, 10th edition, 2024) recommends offering informed men at average risk aged 50–69 PSA testing every two years if they choose regular testing. It recommends testing every two years from age 45 for men at moderately increased risk because of family history, and from age 40 for those at high risk due to family history, through age 69.

USANZ’s published PSA position statement is described as an interim document pending updates to the PCFA and RACGP guidelines. It supports an individualised, risk-based discussion for well-informed men over 50 with an adequate life expectancy, earlier testing from over 45 for men with a family history or higher-risk ethnicity, and from over 40 for men with a BRCA2 mutation.

Since those documents, the NHMRC approved the 2026 Guidelines for the Early Detection of Prostate Cancer in Australia. These are the latest national recommendations and give the following general pathway for people who decide to test after discussion with their GP:

Age and risk General testing approach
Average risk, age 50–69 Offer PSA testing every two years.
Higher risk, age 45 and over Offer testing every two years, using lower PSA levels to trigger a repeat test and possible referral.
Age 70 and over Individualise the decision. The guideline generally considers testing when estimated life expectancy is more than seven years.
Age 45–49, not at higher risk Routine testing is not recommended; an initial test may be discussed if the person is interested.

The 2026 guideline defines higher risk to include having a brother with prostate cancer; a father diagnosed before age 65; two or more second-degree relatives who died from prostate cancer; Black sub-Saharan ancestry; or a confirmed BRCA2 mutation. Family-history details and other health factors still need to be discussed with a GP. The guideline uses age- and risk-specific PSA action levels; a result at or above an action level is generally repeated within one to three months, rather than treated as a cancer diagnosis.

These recommendations guide discussion; they are not a substitute for individual advice. Screening recommendations apply to people without symptoms. If you have symptoms, your GP may recommend assessment regardless of your age or the usual testing interval.

How important is family history?

Family history can make a real difference. Prostate cancer in a close relative, especially a brother, or a father diagnosed at a younger age, can increase a person’s risk and may mean discussing PSA testing earlier than age 50. Multiple affected relatives can also point to an inherited risk. A known BRCA2 mutation is another important risk factor.

If you know that prostate cancer has affected your family, tell your GP which relative was affected and how old they were when diagnosed. Also mention any known breast, ovarian, pancreatic or other cancers in the family, as these may help the GP decide whether genetic counselling or testing should be discussed. Do not wait for symptoms before raising a strong family history.

When should I see a urologist?

Your GP is usually the right first contact. A referral to a urologist may be appropriate if a repeat PSA remains at or above the age- and risk-based action level, if the prostate examination is concerning, or if MRI or other findings suggest that specialist assessment is needed. A urologist can discuss the benefits and limits of further tests, including MRI and biopsy, and help decide on next steps.

Make an appointment with your GP if you notice persistent or new urinary problems, blood in your urine or semen, or ongoing unexplained pain. These symptoms can have many causes and do not automatically mean prostate cancer, but they deserve assessment. Do not wait for a routine PSA check if you have a concerning symptom. If you cannot pass urine, seek urgent medical care.

A useful Movember conversation

Ask your GP: “Given my age, health and family history, should I have a PSA test? If we test, how often should I repeat it, and what would we do if it is raised?” Knowing your family history and discussing the possible benefits and harms can make the decision more useful than simply ordering a blood test without a plan.

Movember is a reminder to look out for one another. Start the conversation, share what you know about your family history, and encourage the men in your life to seek advice when something does not feel right.

This article provides general information and is not a substitute for personal medical advice. PSA testing is a shared decision between you and your healthcare professional.

References and further information

  1. Prostate Cancer Foundation of Australia. 2026 Guidelines for the Early Detection of Prostate Cancer in Australia: summary and recommendations. NHMRC approved 18 May 2026.
  2. The Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice, 10th edition — prostate cancer, recommendations updated 28 June 2024.
  3. Urological Society of Australia and New Zealand. PSA Testing position statement. Interim guidance pending updated guidelines.
  4. Huang S, Chen DC, Crowe J, et al. Navigating the shift: New RACGP Red Book guidelines for prostate-specific antigen testing in general practice. Australian Journal of General Practice. 2025;54(12). Article PDF.

Movember: Men’s mental health

Movember: Men’s mental health and suicide prevention in Australia

Content note: This article discusses suicide. If you are in immediate danger, call 000. Support contacts are listed below.

Movember gives us a visible reminder to talk about men’s health. The moustache can start a conversation, but the more important work is noticing when someone is struggling, listening without judgement and helping them connect with support.

Mental health difficulties are common, treatable and not a personal failure. Suicide is complex: it rarely has one cause, and a difficult period does not mean a person is destined to reach crisis. Timely support, connection and practical help can make a difference.

The Australian picture

The latest Australian Bureau of Statistics (ABS) release available for this article covers deaths registered in 2025. It recorded 3,283 deaths by suicide, including 2,425 males—73.9% of the total. The male age-standardised rate was 17.3 deaths per 100,000 males. The 2025 figures are preliminary and may be revised as coronial investigations are completed. [1]

Age-standardised rates allow comparisons between populations with different age structures. The age-specific rates below are deaths per 100,000 people in the same age group; they describe population patterns, not an individual’s likelihood of suicide.

Age group Male suicide rate in 2025 (per 100,000) What the ABS reported about recorded risk factors
15–24 9.5–18.1 (15–19: 9.5; 20–24: 18.1) Suicide ideation was the most commonly recorded risk factor for people under 25. For children aged 5–17, recorded factors also included education, family and peer relationships, social environment and prior self-harm.
25–44 19.7–26.0 (25–29: 19.7; 30–34: 23.1; 35–39: 26.0; 40–44: 23.3) Relationship circumstances were the most commonly recorded risk factor in this age range. Psychoactive substance use was also frequently recorded.
45–64 23.0–26.8 (45–49 was the peak at 26.8) Mood disorders, including depression, were the most commonly recorded risk factor for people aged 45–84.
65–84 16.2–22.8 Rates varied across these age bands; mood disorders were commonly recorded. Illness, pain and disability may also affect wellbeing and quality of life.
85 and over 24.9 Limitation of activities due to illness or disability was the most commonly recorded risk factor in this age group.

These age bands summarise the ABS’s five-year age data. In 2025, the highest male age-specific rate was among men aged 45–49 (26.8 per 100,000); the largest proportion of male deaths occurred among men aged 35–39 (10.7%). Both figures matter, but they measure different things. [1]

The ABS also records risk factors mentioned in preliminary death registrations. In 2025, the most frequently recorded factors across all people who died by suicide were mood disorders (35.8%), suicidal ideation (30.7%), problems in spousal relationship circumstances (26.7%), a personal history of self-harm (24.3%), and anxiety or stress-related disorders (21.9%). Several factors can be recorded for one person. These are not proof that any single factor caused a death, and the data may change as investigations are finalised. [1]

Mental health concerns can look different from one man to another

In the ABS National Study of Mental Health and Wellbeing, conducted in 2020–2022, 18.3% of males aged 16–85 reported a 12-month mental disorder. Anxiety disorders were reported by 13.3%, affective disorders (including depression) by 6.5%, and substance-use disorders by 4.4%. The equivalent substance-use figure for females was 2.1%. The survey found the highest prevalence of any 12-month mental disorder among males aged 16–24 (32.4%); prevalence declined across older age groups. These are survey estimates, not current-year suicide rates, and they do not mean that everyone with a mental disorder is suicidal. [2]

Depression and anxiety may involve persistent low mood, loss of interest, worry, panic, irritability, poor concentration, sleep changes or feeling overwhelmed. Some men describe distress mainly through anger, pulling away from family or friends, working excessively, taking more risks, or relying more heavily on alcohol or other drugs. These signs are not a diagnosis, but a lasting change from someone’s usual self is a good reason to check in. [3]

There is no single cause

Mental health and suicide risk develop through an interaction of individual, social and economic circumstances. A person may be affected by one issue or many at once. Factors that can contribute to distress include:

  • depression, anxiety, trauma, other mental health conditions or a previous episode of self-harm;
  • relationship conflict, separation, family stress, loneliness or bereavement;
  • financial pressure, unemployment, job insecurity, workplace stress or legal problems;
  • harmful alcohol or other drug use, which can worsen mood, judgement and coping;
  • chronic illness, pain, disability, sleep problems or loss of independence;
  • discrimination, bullying, violence, social exclusion or barriers to culturally safe care;
  • limited social support, or feeling unable to ask for help.

These are possible contributors, not a checklist that predicts what one person will do. A 2025 analysis of the Australian Ten to Men longitudinal study found that the onset of suicidal thoughts was associated with depressive symptoms, disability, financial stress, lower education, sexual orientation and a history of partner violence. The study also found that suicidal thoughts remitted for many men over time, an important reminder that suicidal thinking can change and support can help. Associations in a study do not establish that a factor causes an outcome. [4]

Ideas about having to cope alone or always appear strong can make it harder for some men to talk openly or seek help. This is not true of every man, and strength, responsibility and care for others can also support recovery. A 2025 Australian review found a broad range of formal and informal services for men, while noting that evidence about their effectiveness remains uneven. Services are more useful when they are accessible, respectful and responsive to the person in front of them. [5]

How to support a mate, partner or family member

Movember shares the ALEC approach, developed by R U OK?, as a simple guide for a supportive conversation: [6]

  • Ask how he is going and mention a change you have noticed: “You haven’t seemed yourself lately. How are things really going?”
  • Listen without judgement or rushing to solve everything. Give him time to speak.
  • Encourage action: offer to help contact a GP, counsellor or trusted person, or to go with him to an appointment.
  • Check in again. A message or planned catch-up can show that your support continues after the first conversation.

If you are worried he may be thinking about suicide, ask clearly and calmly whether he is thinking about suicide. Take the answer seriously. You do not need to manage the situation alone: involve a trusted person and contact a crisis service or health professional. If there is immediate danger, call 000 or go to an emergency department.

Getting help in Australia

  • Immediate danger: call 000 or attend an emergency department.
  • Lifeline: call 13 11 14 for 24/7 crisis support. [7]
  • Suicide Call Back Service: call 1300 659 467 for 24/7 telephone and online counselling. [8]
  • MensLine Australia: call 1300 78 99 78 for telephone and online counselling for men. [9]
  • Beyond Blue: call 1300 22 4636 for mental health support and information. [10]
  • Your GP: can discuss symptoms, safety, treatment options and referrals. If you are not sure where to start, a GP appointment is a practical first step.

If you are supporting someone, stay connected and help them access care. If you are struggling yourself, you deserve support too. You do not have to wait until things feel unbearable before reaching out.

A Movember conversation can matter

Movember’s focus on prevention, early intervention and social connection is a useful invitation to check in, not only during November, but throughout the year. The first conversation does not need to be perfect. Ask, listen, help with one next step and follow up.

This article is general information and is not a substitute for individual medical or mental health advice.

References

  1. Australian Bureau of Statistics. Intentional self-harm (suicide) deaths, 2025. Preliminary registered-death data; includes age-specific rates and risk factors.
  2. Australian Bureau of Statistics. National Study of Mental Health and Wellbeing, 2020–2022.
  3. Movember. Spot the signs of poor mental health.
  4. Haregu T, Armstrong G. Understanding the onset and remission of suicidal thoughts in Australian men: Findings from the Ten to Men study. Australian & New Zealand Journal of Psychiatry. 2025. doi:10.1177/00048674251333572.
  5. Slade A, Reily NM, Fujimoto H, et al. Men’s mental health and suicide prevention service landscape in Australia: a scoping review. BMC Public Health. 2025;25:1593. doi:10.1186/s12889-025-22676-6.
  6. Movember. ALEC conversation strategy. Movember credits R U OK? for developing the ALEC model.
  7. Lifeline Australia. Lifeline Crisis Support.
  8. Suicide Call Back Service. Get support.
  9. MensLine Australia. Contact MensLine.
  10. Beyond Blue. Men’s mental health.

Support Movember

Help stop men dying too young: support Movember

Every November, the moustache gives us a reason to start a conversation. But Movember is about much more than facial hair. It brings attention to the health issues that affect men and boys, and supports work in prostate cancer, testicular cancer, mental health and suicide prevention.

I’m raising funds for these causes because they touch the lives of our dads, brothers, sons, partners, friends and mates. A diagnosis, a difficult period with mental health, or the loss of someone to suicide can affect an entire family and community.

Why this matters

You may have seen the message that men die, on average, six years earlier than women. The figure depends on the population and source: Movember’s current Australian campaign reports around four years in Australia and 4.5 years globally. The difference is a reminder that men’s health deserves attention throughout the year, not only when a problem becomes hard to ignore.

Movember focuses on prostate cancer, testicular cancer, mental health and suicide prevention. Donations support programs and research across these areas. The charity also encourages men to look after their health, stay connected and reach out when they need support.

How you can help

If you’re able, please consider making a donation through my Mo Space. Every contribution helps support Movember’s work. Sharing the page or talking about men’s health with someone you care about also helps keep these issues in view.

Donate via my Mo Space:

 

QR Code

 

Thank you for supporting this cause: for all the dads, brothers, sons and mates in your life.

Together, we can help stop men dying too young.


Movember’s current information and cause areas: Movember Australia – Our cause and Movember Australia – FAQs.

Prostate cancer, Movember and the moustache: a conversation worth having

Each November, a moustache can do more than change a face. It can open a conversation that might encourage someone to learn their risk, ask about testing or support a person affected by prostate cancer.

Movember is a good time to talk about prostate cancer, but the message matters all year. The aim is not to alarm every man or suggest that everyone needs the same test. It is to make sure people know the facts and can make an informed decision with their doctor.

Prostate cancer in Australia

Prostate cancer is common. The Australian Institute of Health and Welfare (AIHW) estimated that around 29,000 men would be diagnosed in 2025, making it the most commonly diagnosed cancer in Australian men and accounting for about 30% of cancers diagnosed in men that year. These are projected figures, not a final count. Around 1 in 5 men are expected to be diagnosed with prostate cancer during their lifetime.

The outlook is often very good: the AIHW reports a 96% five-year relative survival rate for prostate cancer diagnosed in 2017–2021. That is a population statistic, not a prediction for any one person. Prostate cancers vary: some grow slowly and may never cause harm, while others can be aggressive and need timely treatment. Early assessment can help identify cancers that are more likely to matter, while careful risk assessment helps avoid unnecessary tests and treatment.

What does Movember mean?

Movember began with a simple idea: grow a moustache, raise funds and get people talking about men’s health. It has grown into a global movement supporting men’s health, including prostate cancer, testicular cancer, mental health and physical activity.

The moustache is a friendly, visible conversation starter. Someone may ask, “Why the Mo?” and that gives you a chance to mention prostate cancer, ask a friend whether he knows his family history, or check in with someone who is going through diagnosis or treatment. A moustache cannot detect cancer, and growing one does not replace medical advice. Its value is in helping make a sometimes awkward subject easier to raise.

How is prostate cancer found?

Prostate cancer often causes no symptoms in its early stages. Urinary symptoms such as a weaker stream, needing to urinate more often or difficulty starting are common with ageing and an enlarged prostate, and do not by themselves mean cancer. Blood in the urine or semen, persistent pain, or a new urinary problem should be discussed with a doctor.

The first step in early detection is usually a conversation about personal risk and the possible benefits and downsides of testing. A prostate-specific antigen (PSA) blood test measures a protein made by the prostate. PSA can rise for reasons other than cancer, including prostate enlargement, infection or inflammation. A raised result is not a diagnosis, and a low result does not rule out every cancer.

Australia’s updated national early-detection guidelines, approved by the National Health and Medical Research Council in May 2026, recommend discussing individual risks, preferences, benefits and possible harms before starting PSA testing. For men who choose testing, the guidelines recommend offering it every two years from age 50 to 69 for those not at higher risk, and from age 45 for those at higher risk. Higher risk includes a relevant family history, a confirmed BRCA2 gene mutation or Black sub-Saharan ancestry. Men aged 70 and over should discuss whether to continue testing in light of their health and preferences. These are discussion points, not a substitute for individual medical advice.

If a PSA result is higher than expected, a doctor may repeat the test and consider other information, such as age, symptoms, family history and examination findings. A urologist may recommend a prostate MRI to help decide whether a biopsy is appropriate and, if so, where to take samples. A biopsy is currently the test that confirms a diagnosis and provides information about the cancer’s grade. Not everyone with an elevated PSA needs a biopsy, and no test is perfect. If cancer is found, the next steps depend on its grade and stage, the person’s health and their preferences; some lower-risk cancers can be monitored with active surveillance.

Make November a reason to check in

This November, consider wearing blue when you walk, jog, run or volunteer at your local parkrun. Invite a friend or family member to join you. It is a simple way to show support, start a conversation and make space for men’s health alongside the usual weekend catch-up. This is a community invitation, not a claim that parkrun is running an official Movember campaign.

If you are unsure whether PSA testing is right for you, speak with your GP. Mention your age, family history and any symptoms, and ask what a result could mean and what the next steps might be. If someone close to you has prostate cancer, listening and offering to go with them to an appointment can be a practical form of support.

Grow a Mo, wear blue, or simply start the conversation. The moustache is the prompt; informed choices and looking out for one another are the point.

This article provides general information and is not a substitute for advice from your doctor. Testing decisions should be made with a health professional who can consider your personal circumstances.

References and further information

  1. Australian Institute of Health and Welfare. Cancer data in Australia: Overview of cancer in Australia, 2025.
  2. Australian Institute of Health and Welfare. Cancer outcomes improving overall.
  3. Prostate Cancer Foundation of Australia. PSA testing and the 2026 Australian early-detection guidelines.
  4. Prostate Cancer Foundation of Australia. Diagnosis of prostate cancer.
  5. Movember. About Movember.
  6. parkrun Australia. Find a parkrun event.

Movember, King Charles and the Prostate: Why Men Shouldn’t Ignore Their Health

Movember, King Charles and the Prostate: Why Men Shouldn’t Ignore Their Health

A moustache can start a conversation. A conversation can sometimes save a life.

Every November, moustaches begin appearing on faces around Australia and across the world. Some are magnificent. Some are questionable. Some probably deserve their own urological assessment.

But behind the facial hair lies an important message.

Movember is about getting men talking about their health.

What began in Melbourne in 2003 with 30 men growing moustaches has developed into an international men’s health movement focusing particularly on prostate cancer, testicular cancer, mental health and suicide prevention. Movember reports that it has funded more than 1,320 men’s health projects around the world.

And few recent stories demonstrate the importance of men paying attention to their health better than that of King Charles III.


First, an important clarification: King Charles does NOT have prostate cancer

This point has frequently been confused in media and social-media discussions.

In January 2024, Buckingham Palace announced that King Charles was receiving treatment for an enlarged prostate.

This was benign prostatic enlargement, commonly called benign prostatic hyperplasia or BPH. It is extremely common as men get older and is not prostate cancer.

The King underwent a planned hospital procedure for his enlarged prostate.

During this episode of care, however, doctors identified a separate abnormality. Further investigations subsequently diagnosed a form of cancer.

Buckingham Palace specifically confirmed that the King’s cancer was not prostate cancer. The precise type of cancer has remained private.

That distinction matters.

But so does what happened next.


A prostate problem led to something else being discovered

The King’s story provides an interesting lesson for men’s health.

He sought medical attention for a prostate problem.

He underwent investigation and treatment.

During that process, doctors discovered another potentially important medical condition.

In February 2024 Buckingham Palace announced that the King had begun a programme of regular cancer treatments and temporarily reduced his public-facing duties.

By April 2024, following treatment and recuperation, he was able to return to public-facing duties.

The exact cancer treatment has never been publicly disclosed, and it would therefore be inappropriate to speculate whether he has received surgery, radiotherapy, chemotherapy, immunotherapy or another form of treatment.

More recently, the King has continued to speak publicly about his cancer experience. In December 2025 he announced that, following early diagnosis, treatment and adherence to medical advice, his treatment schedule could be reduced in the following year.

In June 2026 he and Queen Camilla hosted a reception marking the 125th anniversary of Cancer Research UK, of which the King has been Patron since 2024.

His message has increasingly centered on a simple theme:

Early diagnosis matters.


The other royal problem: an enlarged prostate

For a urologist, the first part of the King’s story is equally important.

An enlarged prostate is extraordinarily common.

As the prostate enlarges, it can compress the urethra and interfere with the passage of urine.

Men may notice:

  • a slower urinary stream
  • difficulty starting urination
  • stopping and starting
  • straining
  • feeling that the bladder has not emptied completely
  • getting up several times during the night
  • urgency or frequency
  • occasionally an inability to pass urine at all.

These symptoms do not automatically mean prostate cancer.

Most commonly they are associated with benign prostate enlargement.

But that does not mean they should simply be accepted as part of getting older.


“It’s probably just my prostate”

Possibly.

But that is precisely why it is worth having it checked.

Assessment of urinary symptoms may include a discussion about symptoms and medications, examination, urine testing, kidney function, PSA testing where appropriate, urinary flow measurement, ultrasound assessment of bladder emptying and occasionally further investigations.

The objective is not simply to find prostate cancer.

It is to work out why the urinary system is behaving differently.


What about prostate cancer?

This is where Movember becomes particularly relevant.

Prostate cancer remains the most commonly diagnosed cancer in Australian men. Australian Institute of Health and Welfare data indicate that prostate cancer accounted for approximately 28% of cancers diagnosed in Australian males in 2024.

AIHW’s updated projections estimate approximately 26,397 prostate cancer diagnoses in Australia during 2026, although it is important to recognise that this is a projection rather than a final observed case count.

Movember estimates that approximately one in five Australian men will be diagnosed with prostate cancer during their lifetime.

And there is another important difference between prostate cancer and benign enlargement:

Early prostate cancer frequently causes no urinary symptoms at all.

Waiting until something hurts or the urine flow deteriorates is therefore not an effective prostate cancer detection strategy.


The PSA conversation

A PSA blood test can help identify men who may require further investigation for prostate cancer.

But PSA is not simply a “cancer test”.

PSA can be elevated for several reasons, including:

  • benign prostate enlargement
  • prostatitis or inflammation
  • urinary infection
  • recent instrumentation
  • urinary retention
  • and prostate cancer.

An abnormal PSA therefore does not automatically mean cancer.

Similarly, decisions about PSA testing should consider a man’s age, family history, previous PSA results, general health and individual risk factors.

The important step is having the conversation with your GP or urologist rather than avoiding the subject altogether.


And if prostate cancer is found?

Modern prostate cancer treatment is no longer a simple choice between “operate” and “do nothing”.

Depending upon the PSA, MRI findings, biopsy grade, tumour volume, stage, age and general health of the patient, options may include:

Active surveillance for suitable low-risk disease.

Robotic-assisted radical prostatectomy for appropriate localised cancers.

Radiation therapy, sometimes combined with hormonal treatment.

Focal therapies in carefully selected patients and specialised settings.

Androgen deprivation and newer androgen-receptor targeted treatments for more advanced disease.

Chemotherapy and radioligand therapies for selected advanced cancers.

The right treatment is increasingly personalised to both the biology of the cancer and the priorities of the man sitting in front of us.


Treatment is not only about surviving cancer

This is another area in which organisations such as Movember have made an important contribution.

Men understandably want their cancer controlled.

But they also care about what happens afterwards.

Will I leak urine?

Will I still have erections?

What happens to ejaculation and orgasm?

Can I continue working?

How will treatment affect my relationship?

Will I still feel like myself?

Movember has invested not only in prostate cancer research but also in projects examining quality of life, urinary function, sexual function and outcomes following treatment. The Prostate Cancer Outcomes Registry Australia and New Zealand, for example, collects patient-reported outcomes including urinary, bowel and sexual function after prostate cancer diagnosis and treatment.

These aren’t embarrassing side issues.

They are part of treating the whole man.


So what does King Charles have to do with Movember?

Quite a lot, despite the fact that he does not have prostate cancer.

His story began with something millions of older men experience:

an enlarged prostate.

Instead of ignoring it, he sought treatment.

That interaction with the healthcare system resulted in another cancer being discovered.

And by publicly announcing his prostate treatment and subsequent cancer diagnosis, the King did something particularly useful for men’s health:

he made it easier to talk about it.

That is essentially what Movember has been trying to achieve for more than two decades.

A moustache is simply the billboard.

The conversation is the important bit.


My Movember message to men

If your urinary stream isn’t what it used to be, get it checked.

If you’re getting up repeatedly during the night, ask why.

If you’re struggling with erections, don’t be embarrassed to mention it.

If you notice a testicular lump, don’t wait.

If prostate cancer runs in your family, discuss your individual risk.

And if you’ve been putting off that conversation about PSA testing, perhaps Movember is a good time to have it.

Men are remarkably good at servicing cars, replacing batteries, checking tyre pressures and investigating strange noises coming from engines.

We are sometimes considerably less enthusiastic when the strange noise is coming from ourselves.

This Movember, grow the moustache if you wish.

But more importantly:

Have the conversation.
Know your prostate.
Know your risk.
And don’t ignore a change in your body simply because it’s embarrassing to talk about.

Your prostate may be small.

Its ability to cause trouble is disproportionately ambitious.


References and further reading

  1. The Royal Family. A Statement from Buckingham Palace. 5 February 2024. Buckingham Palace confirmed that a separate cancer was discovered during treatment for benign prostate enlargement.
  2. The Royal Family. The King returns to public-facing duties. April 2024.
  3. The Royal Family. A message from The King in support of Stand Up To Cancer. December 2025.
  4. The Royal Family. The King and Queen host a reception for Cancer Research UK. June 2026.
  5. Australian Institute of Health and Welfare. The health of men in Australia. Prostate cancer statistics and Australian cancer burden.
  6. Australian Institute of Health and Welfare. Cancer data in Australia: Prostate cancer projection method changes and updated long-term projections. Updated July 2026.
  7. Movember. Prostate Cancer: Prostate Cancer Action, Innovation & Collaboration. Australian prostate cancer statistics and research programs.
  8. Movember. Our Story. History of the Movember movement from Melbourne in 2003.
  9. Movember. Prostate Cancer Outcomes Registry Australia and New Zealand. Patient outcomes and quality-of-life research.

Medical disclaimer

This article provides general information and should not replace individual medical assessment. Urinary symptoms, an abnormal PSA or concerns about prostate cancer should be discussed with your GP or urologist.

Hydronephrosis: what it means and how it is treated

Finding out that a kidney is swollen on a scan can be worrying. The word hydronephrosis sounds like a diagnosis, but it describes an appearance: urine is collecting and stretching the drainage system of one or both kidneys. It is a sign that needs to be understood in context. It does not, by itself, tell us why it has happened, whether a cancer is present, or whether an operation is needed.

Many causes are treatable, and some cases can be monitored safely. The right approach depends on the cause, the degree and duration of blockage, kidney function, symptoms, overall health and, when cancer is involved, what matters most to the person receiving care.

What are unilateral and bilateral hydronephrosis?

Each kidney drains urine through a tube called a ureter into the bladder. Unilateral hydronephrosis affects one kidney; bilateral hydronephrosis affects both. A blockage may be within the kidney or ureter, or lower down where it affects the bladder outlet. A full bladder or difficulty emptying can sometimes cause dilation on both sides.

One healthy kidney can often maintain overall kidney function when the other side is obstructed. This can mean that a person with a one-sided blockage has few symptoms and normal blood tests. With obstruction affecting both kidneys, or a person who has only one functioning kidney, kidney function can become impaired more quickly. The scan appearance alone does not show how well each kidney is working.

What can cause hydronephrosis?

Causes may be benign (non-cancerous) or malignant (related to cancer). They include:

  • Kidney or ureteric stones, which may block urine flow and cause pain, blood in the urine or infection.
  • Narrowing or scarring of the ureter (a stricture), sometimes following previous surgery, instrumentation, infection or radiation treatment.
  • Bladder outlet obstruction or poor bladder emptying, including from an enlarged prostate before prostate surgery, urethral narrowing, a tight bladder-neck/anastomotic scar after surgery, or a bladder that does not contract effectively.
  • Anatomical or functional conditions, such as a narrowing where the kidney joins the ureter (a pelvi-ureteric junction obstruction), reflux of urine towards the kidney, or in some circumstance, pregnancy.
  • Blood clots or inflammation, which can temporarily obstruct drainage.
  • Cancer, either growing in the urinary tract or pressing on a ureter from nearby tissues or lymph nodes. Possible cancers include prostate, bladder, bowel, gynaecological and other pelvic or abdominal cancers. A cancer-related cause is only one possibility; imaging and clinical assessment are needed to establish the cause.

Prostate cancer and hydronephrosis

Prostate cancer can affect urine drainage in different ways. A locally advanced tumour may involve the bladder outlet or the area where the ureters enter the bladder. Cancer in pelvic or abdominal lymph nodes can press on one or both ureters. These problems are more likely with locally advanced or recurrent disease than with an early cancer confined to the prostate, but each person’s situation is different.

Hydronephrosis in someone who has had prostate cancer does not automatically mean the cancer has returned. Stones, infection, scarring, bladder-emptying problems and unrelated conditions remain possible. The team will consider the person’s history, prostate-specific antigen (PSA) trend, symptoms, blood and urine tests, and the pattern seen on imaging. Further tests may be appropriate if the cause is not clear.

After radical prostatectomy

After prostate removal, the bladder is joined to the urethra. Scarring at this join (a vesicourethral anastomotic stenosis, sometimes called a bladder-neck contracture) can make it difficult to empty the bladder. Significant retention may raise pressure in the bladder and contribute to dilation of both upper urinary tracts. A ureteric injury or later narrowing is a less common possibility. Recurrent cancer or enlarged lymph nodes can also obstruct a ureter, but this is not the only explanation.

Assessment may include checking bladder emptying, kidney function and imaging, with a camera examination or contrast study if needed. Treatment is directed at the level and cause of the blockage: for example, bladder drainage, treatment of a narrowing, or drainage of an obstructed ureter.

After salvage radiation therapy

Radiation can cause inflammation and, less commonly, delayed scarring in urinary tissues. Narrowing of the urethra or bladder outlet can interfere with emptying. A ureteric stricture after pelvic radiation is uncommon, but may develop months or years later. Salvage radiation after prostatectomy is generally directed to the prostate bed; hydronephrosis that appears afterwards still needs a proper assessment rather than being assumed to be a radiation effect or a cancer recurrence.

If imaging shows a narrowed ureter, the team may use CT or MRI, a contrast study, or a functional kidney scan to clarify its site, length and effect on kidney drainage. Treatment can be more complex in previously irradiated tissue, so decisions are individualised and may involve a reconstructive urologist, radiation oncologist, medical oncologist or interventional radiologist.

Symptoms and when to seek urgent care

Hydronephrosis can cause no noticeable symptoms, particularly when it develops gradually or affects one kidney. When symptoms occur, they may include pain in the side, back or abdomen; nausea or vomiting; blood in the urine; difficulty passing urine; or repeated urinary infections.

Please seek urgent medical assessment for fever or shaking chills with suspected urinary blockage, severe or worsening pain, repeated vomiting, very little or no urine, confusion, or feeling suddenly very unwell. Infection behind a blockage can become serious and may need urgent antibiotics and drainage. Sudden inability to pass urine also needs prompt care.

How is it investigated?

The first aim is to understand whether there is a blockage that needs prompt relief and what is causing it. Assessment commonly includes:

  1. A conversation and examination, including previous cancer treatments, operations, stones, infections, urinary symptoms and medicines.
  2. Blood tests, especially creatinine and estimated kidney function, and urine tests for infection or blood.
  3. Ultrasound, which can show dilation of the kidneys and bladder and whether the bladder empties.
  4. CT or MRI, selected according to the suspected cause and the person’s kidney function, to look for stones, strictures, masses or enlarged lymph nodes.
  5. Additional tests where useful: a MAG3 renal scan can assess each kidney’s contribution and drainage; cystoscopy or contrast X-rays can clarify the bladder outlet or ureter.

Not everyone needs every test. The clinician will choose investigations that answer the question while taking account of kidney function, previous treatment and the person’s circumstances.

Management options

Treatment is tailored to the cause and the degree of risk. The goals may be to protect kidney function, treat infection or pain, restore urine flow, enable other cancer treatment, or support comfort and quality of life.

Observation and treatment of the cause

Mild, stable hydronephrosis may sometimes be monitored with repeat blood tests and imaging, particularly if there is no infection, troublesome pain or evidence of kidney function decline. A stone may pass or be treated with medication, ureteroscopy or another stone procedure. Infection is treated with antibiotics. Retention may be relieved with a bladder catheter while the cause is assessed. A benign narrowing may be treated by endoscopic incision or dilation, reconstruction, or another procedure depending on its location and the person’s health.

Draining the kidney

If drainage is needed, there are two common approaches:

  • Ureteric stent (often called a JJ stent): a thin internal tube placed between the kidney and bladder, usually using a camera. It can avoid an external collection bag, but may cause urinary frequency, urgency, discomfort, blood in the urine or infection, and it usually needs planned replacement or removal. A tight narrowing or external cancer pressure can make stent placement difficult or less reliable.
  • Percutaneous nephrostomy: a small tube placed through the skin of the back into the kidney, usually by an interventional radiologist, to drain urine into an external bag. It can be useful when a stent cannot be placed, has not drained adequately, or rapid reliable drainage is needed. The tube needs care and periodic changes and can affect daily activities.

The choice depends on the site and cause of obstruction, infection, anatomy, kidney function, expected duration, other treatment plans and personal preference. Sometimes a nephrostomy is used first, with an internal stent considered later. Drainage can relieve pressure and help kidney function, but it does not remove the underlying cause; further treatment or monitoring is often needed.

When might palliative care be part of the plan?

“Palliative” can sound frightening, but palliative care is focused on comfort, symptom relief, support and quality of life. It can be provided alongside active cancer treatment. It does not mean that someone is being abandoned or that all treatment has stopped.

When hydronephrosis is caused by advanced cancer, a stent or nephrostomy may help with pain, infection, kidney function, or the ability to receive cancer treatment. It can also bring burdens such as procedures, hospital visits, tube or stent symptoms, repeat exchanges and complications. In some situations, drainage may not improve symptoms or kidney function enough to outweigh those burdens. Evidence in this area is limited, and outcomes vary widely; population averages cannot predict an individual person’s future.

There is no single point at which palliation is “required.” The decision is made with the patient, their chosen supports and the treating team. It can help to discuss:

  • What problem are we hoping drainage will improve?
  • How likely is it to help, and how soon might we know?
  • What would living with a stent or nephrostomy involve?
  • Could the result allow another treatment that matters to me?
  • What might happen if we monitor or manage symptoms without drainage?
  • What matters most to me now: time at home, symptom relief, kidney function, further cancer treatment, or avoiding procedures?

Choosing not to have a procedure is also a valid choice when it best fits a person’s wishes and clinical circumstances. The team can still treat pain, nausea, infection and other symptoms, and provide practical and emotional support. These conversations are best held early and revisited as circumstances change.

In summary

Hydronephrosis means that urine is collecting in one or both kidneys, but it does not identify the cause on its own. Many causes are benign and treatable. Prostate cancer, previous prostate surgery and radiation can be relevant, but a careful assessment is needed before drawing conclusions. Some people need urgent drainage; others can be monitored or treated in a less invasive way. When cancer is advanced, decisions about drainage and palliative care should be compassionate, individualised and guided by what is most important to the person.

References and further reading

  1. National Kidney Foundation. Hydronephrosis. Updated 2023.
  2. Mayo Clinic. Hydronephrosis: Diagnosis and treatment. Updated 2024.
  3. European Association of Urology. EAU Guidelines on Urolithiasis. See section on sepsis and anuria in an obstructed kidney.
  4. National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management (NG131). Includes recommendations on upper urinary tract decompression for obstructive uropathy secondary to hormone-relapsed prostate cancer.
  5. Chorbińska J, Krajewski W, Zdrojowy R. Urological complications after radiation therapy—nothing ventured, nothing gained: a narrative review. Transl Androl Urol. 2021;10(8):3553–3566. doi:10.21037/tau-20-1217.
  6. Carilli M, et al. Management of ureteral stricture disease after radiation therapy for pelvic malignancies. Cancers (Basel). 2024;16(21):3561. doi:10.3390/cancers16213561.
  7. Shah M, et al. Malignant upper urinary tract obstruction in cancer patients: a systematic review. BJUI Compass. 2024;5(11):915–925. doi:10.1002/bco2.340.
  8. Gauhar V, et al. Nephrostomy tube versus double J ureteral stent in patients with malignant ureteric obstruction: a systematic review and meta-analysis of comparative studies. Int Braz J Urol. 2022;48(6):903–914. doi:10.1590/S1677-5538.IBJU.2022.0225.

This page provides general information and is not a substitute for an individual assessment by a qualified health professional. If you have hydronephrosis, your clinician can explain what the scan means in your circumstances and whether further tests or treatment are needed.

Prostate cancer with kidney failure: is surgery, focal therapy or radiation the right choice?

A patient guide by Dr Jo Schoeman

A diagnosis of prostate cancer is unsettling. Having chronic kidney disease or needing dialysis can make treatment decisions feel even harder. The reassuring point is that kidney failure does not automatically rule out treatment. The best choice depends on the cancer, the degree of kidney impairment, other medical conditions and, crucially, whether a kidney transplant is planned.

What does Gleason 3+4 mean?

Gleason 3+4=7 is Grade Group 2 prostate cancer. Most of the sampled tumour has pattern 3, with a smaller component of pattern 4. It is generally less concerning than Gleason 4+3=7, but “3+4” alone cannot tell us whether immediate treatment is needed.

I would review the PSA and PSA density, examination, MRI findings, number and length of positive biopsy cores, percentage of pattern 4, any cribriform or intraductal cancer, and whether disease is confined to the prostate. Kidney function, dialysis schedule, life expectancy and transplant eligibility are considered alongside these findings. Some men have favourable intermediate-risk cancer; others have features that make definitive treatment more appropriate. Staging scans are selected according to overall risk rather than biopsy grade alone. [1,2]

Could active surveillance be reasonable?

Yes, for selected men with small-volume, favourable Grade Group 2 cancer. Surveillance means scheduled PSA tests, clinical review, MRI where useful and repeat biopsy when indicated. It keeps treatment available if the cancer changes. It is a particularly meaningful option when another serious illness makes the harms of immediate treatment more likely to outweigh its benefit. It does, however, require a patient who can attend follow-up and accepts a small increased risk of progression compared with immediate treatment. [1,2]

If kidney disease or other illnesses substantially limit life expectancy, watchful waiting may be more appropriate: care focuses on symptoms rather than routine testing intended to trigger curative treatment. This is a separate decision from active surveillance. [1]

Can radical prostatectomy or robotic surgery be performed?

Often, yes. Chronic kidney disease and dialysis are not automatic contraindications to radical prostatectomy. Robotic assisted surgery may offer less blood loss and a shorter hospital stay than open surgery in selected patients, but it still involves general anaesthesia, abdominal insufflation and a head-down operating position. Advanced kidney disease increases the importance of planning for bleeding, infection, fluid and electrolyte balance, medication dosing and postoperative kidney injury. Population studies find higher complication rates in patients with chronic kidney disease, particularly advanced disease; individual risk varies considerably. [3,4]

Before an operation I would coordinate with the nephrologist, anaesthetist and, where relevant, dialysis team. We would assess cardiovascular health, haemoglobin, potassium, anticoagulants, residual kidney function and the timing of dialysis. Surgery also carries the usual risks of urinary leakage or incontinence, erectile dysfunction, infertility, blood clots and possible need for further cancer treatment. Whether a robotic approach is feasible depends on the patient and the surgical team; it is not automatically a safer choice for every person with kidney failure. [1,3,4]

Is focal therapy a better option?

Not simply because the kidneys are failing. Focal therapy treats the visible cancer-bearing portion of the prostate, using a technique such as focused ultrasound, cryotherapy or another ablative method. It may appeal to men hoping to reduce urinary or sexual side effects, but the cancer can be present elsewhere in the gland, and longer-term cancer control is less certain than for established whole-gland treatments. Further MRI, biopsies and sometimes repeat treatment are necessary.

The AUA/ASTRO guideline notes a lack of high-quality comparisons with surgery, radiation and surveillance. European guidance restricts focal treatment to settings with careful prospective follow-up, such as a trial or registry. Kidney disease alone does not establish that focal treatment is preferable. In a suitable patient it can be discussed with a specialist who explains uncertainty, access, costs and a clear follow-up plan. [1,2]

Is radiotherapy an option?

Yes. External beam radiotherapy avoids major surgery and usually does not expose the kidneys directly when treating a prostate confined to the pelvis. Options include moderately shortened courses and, for selected men, more condensed schedules or brachytherapy. The radiation oncologist will tailor treatment to the cancer and urinary function. Depending on whether the disease is favourable or unfavourable intermediate risk, a course of androgen deprivation therapy (ADT) may also be advised; ADT has its own effects on energy, muscle, bone and metabolic health. [1,2]

Radiotherapy may cause temporary urinary frequency, burning or bowel upset; longer-term urinary, bowel or erectile effects are also possible. Existing urinary obstruction and kidney transplant anatomy can change planning. In a transplant recipient, the graft and ureter may sit in the pelvis, so radiation dose constraints require particular attention. Dialysis, by itself, does not make prostate radiation impossible. [1,2]

What if a kidney transplant is planned?

This is a central part of the discussion. A transplant team may need to know whether the cancer is under surveillance or has been treated, its estimated risk of progression and the proposed follow-up. The presence of prostate cancer does not automatically mean that transplantation must wait for a fixed number of years; transplant eligibility is individual and should be discussed directly with the transplant team. A transplanted kidney in the pelvis also affects the planning of later pelvic surgery or radiotherapy. [5]

How do we decide?

Option When it may fit Main trade-off
Active surveillance Low-volume, favourable Grade Group 2 disease Regular testing and a possibility of later treatment
Robotic radical prostatectomy Fit patient seeking definitive local treatment Anaesthetic and surgical risks, with continence and erectile side effects
Radiotherapy Patient seeking definitive treatment without prostate removal Urinary, bowel and sexual effects; ADT may be needed
Focal therapy Carefully selected patient after discussion of uncertainty Less established long-term cancer control and ongoing biopsies
Watchful waiting Limited life expectancy or major competing health risks Treats symptoms if they arise rather than aiming for cure

There is no universal winner between robotic surgery and radiation for Gleason 3+4 cancer with kidney failure. A multidisciplinary discussion involving urology, radiation oncology, nephrology and the transplant team, if applicable, helps align cancer control with kidney health and the patient’s priorities.

This article offers general information and cannot determine treatment for an individual patient. Decisions require review of the pathology, imaging, kidney function and overall health.

References

  1. European Association of Urology. EAU Guidelines on Prostate Cancer: Treatment. Accessed September 2026.
  2. American Urological Association and American Society for Radiation Oncology. Clinically Localized Prostate Cancer Guideline. 2022.
  3. Post-surgical outcomes of patients with chronic kidney disease and end stage renal disease undergoing radical prostatectomy: 10-year results from the US National Inpatient Sample. 2019.
  4. The Effect of Chronic Kidney Disease on Adverse In-Hospital Outcomes at Radical Prostatectomy. 2025.
  5. Kidney Disease: Improving Global Outcomes. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. 2020.

Tranexamic Acid for Radiation Cystitis: Benefits, Duration and Important Risks

Blood in the urine after pelvic radiotherapy can be frightening. It may appear months or even many years after treatment for prostate, bladder, rectal or gynaecological cancer. One possible cause is radiation cystitis: delayed injury to the bladder lining and its small blood vessels.

Tranexamic acid is sometimes considered when bleeding is troublesome. It can help stabilise blood clots, but it does not repair the radiation injury itself and it is not suitable for every patient. In urinary tract bleeding, preventing a clot from dissolving may reduce bleeding but may also allow a larger clot to obstruct the bladder or ureter. Careful patient selection and medical supervision are therefore essential.

Seek urgent medical attention if you cannot pass urine, are passing large clots, feel faint or breathless, develop fever or flank pain, or the bleeding is heavy or worsening.

What is radiation cystitis?

Radiotherapy can cause progressive damage to the bladder’s small blood vessels. These vessels may become fragile and bleed easily. Patients may experience visible haematuria, urinary frequency, urgency, pain or recurrent clot retention.

Radiation cystitis should not be assumed simply because a patient has previously received radiotherapy. Infection, urinary stones, recurrent or new cancer, kidney disease and medication-related bleeding must also be considered. Assessment may include urine testing and culture, a full blood count, renal function, imaging of the upper urinary tract and cystoscopy. Biopsy is used selectively because irradiated tissue heals poorly.

How does tranexamic acid work?

The body normally breaks down blood clots through a process called fibrinolysis. Tranexamic acid blocks the binding of plasminogen and plasmin to fibrin, slowing this breakdown. It is therefore an antifibrinolytic medicine: it helps a clot remain in place rather than acting as a blood-clotting factor itself.

For radiation cystitis, tranexamic acid is intended to control active bleeding. It does not remove abnormal radiation-induced blood vessels, reverse fibrosis or prevent future bleeding once the medicine is stopped.

How effective is it for radiation cystitis?

The evidence is limited. Tranexamic acid has been used for haematuria from several causes, and a small randomised emergency-department study found that intravenous treatment reduced the amount of bladder irrigation required to clear the urine. However, it did not significantly reduce haemoglobin loss or transfusion requirements. Importantly, this study included mixed causes of haematuria and was not designed specifically for radiation cystitis.

The Canadian Urological Association best-practice report concluded that evidence was insufficient to make a formal recommendation for tranexamic acid in radiation-induced haemorrhagic cystitis. Later narrative reviews have reached a similar conclusion. Intravesical tranexamic acid, placed directly into the bladder, has shown encouraging results in small emergency-department studies of gross haematuria, but evidence specific to radiation cystitis is still inadequate and this remains a specialist, non-standard use.

In practice, tranexamic acid may be considered as a temporary adjunct in selected patients while the cause and severity of bleeding are assessed, or while more definitive treatment is arranged. It should not delay bladder washout, clot evacuation, cystoscopic treatment, hyperbaric oxygen therapy, embolisation or other appropriate care when these are required.

How long can tranexamic acid be used?

There is no well-supported universal duration for radiation cystitis. The Australian product information for oral tranexamic acid describes treatment of haematuria while blood remains macroscopically visible, but radiation cystitis is a recurrent condition and that instruction should not be interpreted as approval for indefinite therapy.

For this indication, treatment is generally best regarded as a short, medically supervised course for an active bleeding episode. The exact dose and duration depend on:

  • whether bleeding is mild, ongoing or causing clot retention;
  • whether the source is the bladder or upper urinary tract;
  • kidney function, because tranexamic acid is largely eliminated in the urine;
  • previous blood clots, cardiovascular risk and pro-thrombotic medicines;
  • anticoagulant or antiplatelet therapy; and
  • the response to treatment and need for definitive therapy.

There is no good evidence supporting continuous long-term tranexamic acid as prophylaxis for recurrent radiation cystitis. If bleeding has not clearly improved within a short course, recurs promptly after treatment, or requires repeated courses, the diagnosis and management plan should be reassessed. Longer or repeated use should occur only under specialist supervision, with renal function and thrombotic risk reviewed.

Patients should not start, extend, repeat or stop prescribed tranexamic acid without discussing it with their treating clinician.

Important side effects

Common or less serious adverse effects may include:

  • nausea, vomiting, diarrhoea or abdominal discomfort;
  • headache, dizziness or fatigue; and
  • muscle or joint discomfort.

Potentially serious adverse effects include:

Blood clots

Deep-vein thrombosis, pulmonary embolism, stroke, heart attack and other arterial or venous thromboses are uncommon but potentially serious. Risk assessment is particularly important in patients with an active or previous clot, known thrombophilia, active malignancy, prolonged immobility or concurrent pro-thrombotic medication.

Urgent assessment is required for new unilateral leg pain or swelling, sudden chest pain, shortness of breath, coughing blood, weakness on one side, difficulty speaking or sudden severe headache.

Clot retention and urinary obstruction

Tranexamic acid may stabilise clots within the urinary tract. This can contribute to painful bladder clot retention. It is particularly concerning when bleeding arises from a kidney or ureter, because a clot may obstruct the ureter and cause flank pain, hydronephrosis or loss of kidney function. Upper-tract haematuria therefore warrants particular caution and specialist assessment.

Kidney impairment

Most tranexamic acid is excreted unchanged through the kidneys. The dose must be reduced when renal function is impaired; accumulation increases the risk of toxicity, including neurological adverse effects. Significant renal impairment may make treatment inappropriate or require a substantially altered regimen.

Seizures

Seizures are a recognised, dose-related risk, reported particularly with high intravenous doses and when the medicine accumulates in renal impairment. A history of seizures requires careful consideration.

Visual disturbance

Rare visual effects, including altered colour vision, have been reported. New visual symptoms require prompt review and usually discontinuation pending medical advice. Ophthalmic monitoring may be considered when prolonged treatment is unavoidable.

Severe allergy

Facial or throat swelling, wheeze, breathing difficulty or a widespread blistering rash requires emergency care.

Who may not be suitable for treatment?

Tranexamic acid may be contraindicated or require particular caution in people with:

  • active thromboembolic disease or a substantial history or risk of thrombosis;
  • significant kidney impairment;
  • upper urinary tract bleeding or suspected ureteric obstruction;
  • a history of seizures;
  • acquired disturbances of colour vision;
  • disseminated intravascular coagulation unless managed by an experienced clinician; or
  • hypersensitivity to tranexamic acid.

Medication review is essential. Anticoagulants and antiplatelet agents can worsen bleeding, but stopping them may cause stroke, pulmonary embolism, heart attack or coronary-stent thrombosis. They should not be stopped merely because haematuria develops without an individual risk assessment involving the prescribing clinician. Likewise, combining tranexamic acid with pro-thrombotic medicines requires caution.

Where does it fit in the management pathway?

Management is guided by severity. Initial care may include resuscitation, correction of significant anaemia or coagulopathy, a large-bore catheter, manual washout and continuous bladder irrigation. Cystoscopy permits clot evacuation, exclusion of tumour and cautery or laser treatment of bleeding areas.

For persistent or recurrent radiation cystitis, options may include intravesical agents, hyperbaric oxygen therapy, selective arterial embolisation and, rarely, urinary diversion or cystectomy. Hyperbaric oxygen is one of the better-studied treatments because it aims to improve tissue oxygenation and new blood-vessel formation rather than merely suppressing an episode of bleeding.

Tranexamic acid may have a role as a bridge or adjunct in a carefully selected patient. Its value must always be balanced against the danger of thrombosis and urinary tract obstruction.

The take-home message

Tranexamic acid can reduce haematuria in some patients, but evidence specifically for radiation cystitis is weak. It is not a cure and should usually be used only for a short, active bleeding episode under medical supervision. There is no established safe or effective duration for continuous long-term use in radiation cystitis. Kidney function, clotting history, the anatomical source of bleeding and concurrent medication must be reviewed before treatment.

Visible haematuria after radiotherapy always deserves proper investigation, particularly if it is recurrent, contains clots or is accompanied by difficulty passing urine.

This article provides general information and does not replace individual medical advice. Tranexamic acid is a prescription medicine in Australia; its use for radiation cystitis must be individualised by the treating clinician.

References

  1. Goucher G, Saad F, Lukka H, Kapoor A. Canadian Urological Association Best Practice Report: Diagnosis and management of radiation-induced hemorrhagic cystitis. Can Urol Assoc J. 2019;13(2):15–23. doi:10.5489/cuaj.5788
  2. Moharamzadeh P, Ojaghihaghighi S, Amjadi M, Rahmani F, Farjamnia A. Effect of tranexamic acid on gross hematuria: a pilot randomized clinical trial study. Am J Emerg Med. 2017;35(12):1922–1925. doi:10.1016/j.ajem.2017.09.012
  3. Abramowitz D, et al. Clinical management of radiation cystitis: a narrative review. AME Med J. 2021;6:30. Clinical management of radiation cystitis
  4. Choi H, et al. Impact of intravesical administration of tranexamic acid on gross hematuria in the emergency department: a before-and-after study. Am J Emerg Med. 2023;68:118–122. doi:10.1016/j.ajem.2023.03.010
  5. Pfizer Australia. Cyklokapron (tranexamic acid) Australian Product Information. Current product information should be checked through the Therapeutic Goods Administration or the sponsor before prescribing. Australian product information
  6. DailyMed. Tranexamic acid injection—prescribing information. US National Library of Medicine. DailyMed drug labelling
  7. Chauncey JM, Wieters JS. Tranexamic Acid. In: StatPearls. Updated 2025. NCBI Bookshelf